Compugen (CGEN) Shares Outstanding (Weighted Average) (2009 - 2026)
Compugen's (CGEN) quarterly Shares Outstanding (Weighted Average) came in at $94.6 million in Q1 2026, up 2.44% year-on-year from $92.3 million in Q1 2025, and up 1.21% quarter-over-quarter from $93.4 million in Q4 2025.
Compugen (CGEN) Shares Outstanding (Weighted Average) (2009 - 2026) Analysis & Trends
Compugen has disclosed Shares Outstanding (Weighted Average) across 18 years of filings, most recently posting $94.6 million for Q1 2026.
- Shares Outstanding (Weighted Average) for Q1 2026 came in at $94.6 million, up 2.44% year-over-year; the trailing twelve-month figure through Mar 2026 was $94.6 million (up 2.44% YoY), and the FY2025 annual result was $93.4 million, up 4.35% from the prior year.
- Shares Outstanding (Weighted Average) came in at $94.6 million for Q1 2026 at Compugen, up from $93.4 million in the prior quarter.
- In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $94.6 million in Q1 2026 to a low of $100.0 in Q2 2024.
- The 5-year median for Shares Outstanding (Weighted Average) is $86.6 million (2022), against an average of $65.4 million.
- Across the five-year window, Shares Outstanding (Weighted Average) tumbled 52.38% in 2024 and surged 60.0% in 2025, its largest moves.
- Compugen's Shares Outstanding (Weighted Average) stood at $86.6 million in 2022, then increased by 1.25% to $87.6 million in 2023, then climbed by 2.16% to $89.5 million in 2024, then rose by 4.35% to $93.4 million in 2025, then climbed by 1.21% to $94.6 million in 2026.
- The last three Shares Outstanding (Weighted Average) figures came in at $94.6 million (Q1 2026), $93.4 million (Q4 2025), and $160.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 185,491.37 Bn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 400.00 Bn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 100.00 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 417.01 Bn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 118.76 Bn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 68.88 Bn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 254.10 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 928.40 Mn |
| 10 | Compugen | 189.59 Mn | 97.83 Mn | 352,000.00 | 94.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 94.56 Mn |
| Dec 31, 2025 | 93.43 Mn |
| Jun 30, 2025 | 160.00 |
| Mar 31, 2025 | 92.31 Mn |
| Dec 31, 2024 | 89.53 Mn |
| Jun 30, 2024 | 100.00 |
| Mar 31, 2024 | 89.51 Mn |
| Dec 31, 2023 | 87.63 Mn |
| Sep 30, 2023 | 88.31 Mn |
| Jun 30, 2023 | 210.00 |
| Mar 31, 2023 | 86.62 Mn |
| Dec 31, 2022 | 86.56 Mn |
| Sep 30, 2022 | 86.62 Mn |
| Jun 30, 2022 | 220.00 |
| Mar 31, 2022 | 86.45 Mn |
| Dec 31, 2021 | 84.20 Mn |
| Sep 30, 2021 | 83.98 Mn |
| Jun 30, 2021 | 230.00 |
| Mar 31, 2021 | 83.68 Mn |
| Dec 31, 2020 | 79.59 Mn |